Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute ST Elevation Myocardial Infarction Clear all
Terminated Phase 2 Interventional Results available

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

NCT00719914
View directory record Official record
Conditions
ST-Elevation Myocardial Infarction
Interventions
eptifibatide, normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Ormond Beach, Florida • Rochester, Michigan • Mansfield, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

NCT00910962
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
GW856553, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
45 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post Conditioning + Primary PCI, Standard Primary PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms

NCT04231097
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions
MBCT intervention for ACS patients
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

NCT00093158
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2007 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide in Myocardial Infarction Size

NCT00568061
View directory record Official record
Conditions
Acute Myocardial Infarction, ST Elevation MI, STEMI
Interventions
Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Mobile, Alabama • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 21, 2026, 1:32 PM EDT
Completed No phase listed Observational Results available

National Cardiogenic Shock Initiative

NCT03677180
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Heart Attack
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
75
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

NCT01931852
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Cardiac MRI, ACC/AHA Guideline adherent care
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 21, 2026, 1:32 PM EDT
Active, not recruiting Not applicable Interventional

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358
View directory record Official record
Conditions
Acute Myocardial Infarction, Coronary Artery Disease
Interventions
Physiology-guided NCL PCI, Angiography-guided NCL PCI
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:32 PM EDT
Not listed No phase listed Observational

Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study

NCT02765477
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Multi-modality Imaging in Acute Myocardial Infarction

NCT02926755
View directory record Official record
Conditions
Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery
Interventions
Coronary Angiography
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

NCT00378352
View directory record Official record
Conditions
Acute ST Elevation Myocardial Infarction
Interventions
Epoetin alfa
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction

NCT01936896
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 21, 2026, 1:32 PM EDT
Not listed Phase 4 Interventional

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

NCT05263778
View directory record Official record
Conditions
Cardiovascular Diseases, NSTEMI, STEMI
Interventions
Bempedoic Acid / Ezetimibe Oral Tablet, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 21, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

NCT01539590
View directory record Official record
Conditions
Myocardial Infarction
Interventions
BB3, Normal saline
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New Haven, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Anakinra 100 mg, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI

NCT01625104
View directory record Official record
Conditions
STEMI
Interventions
Non Intervention, Agressive Intervention Process Improvement Strategies
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

NCT00093197
View directory record Official record
Conditions
Myocardial Infarction
Interventions
KAI-9803 for Injection, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 21, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:32 PM EDT